Sotac Pharmaceuticals Limited (NSE: SOTAC) is an Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹144 Cr, it ranks #2,939 by market cap among the 6,197 Indian listed companies on FinBizNet, and #42 of 63 in Pharmaceuticals. At ₹129.35 (as of 16 Nov 2026), the share price is 7.4% below its 52-week high of ₹139.65 and 50.4% above its 52-week low of ₹86.00. The share price is down 0.4% over one year and up 40.7% over three months.
| Current Price | ₹129.35 |
|---|---|
| Market Cap | ₹144 Cr |
| NSE Symbol | SOTAC |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 24.8 |
| Return on Equity | 10.29% |
| Return on Assets | 6.13% |
| 52-Week Range | ₹86.00 – ₹139.65 |
| 1-Year Price Change | -0.4% |
| 3-Month Price Change | +40.7% |
| Beta (1Y) | -0.3 |
| Dividend Yield | 0.15% |
| Headquarters | Ahmedabad, Gujarat |
| Website | sotacpharma.com |
Promoters held 72.85% of Sotac Pharmaceuticals Limited's shares as of Sept 2026, unchanged from Sept 2025.
Sotac Pharmaceuticals Limited engages in the production, manufacturing, processing, and sale of various pharmaceutical products in India. Its therapeutic product portfolio includes anti-diabetic, anti-psychotic, vitamins, minerals, iron supplements, anti-cold, anti-allergic, dermatological solutions, antacid, anti-ulcerants, PPI, anti-emetics, cardiac, anti-hypertensives, analgesic, anti-pyretic, anti-inflammatory, anti-bacterial, anti-viral, general antibiotics, IP-lactams and non-IP-lactams, anti-fungal, and cephalosporin products. The company also offers non-beta lactam general tablets, beta lactam coated tablets, beta lactam uncoated tablets, non-beta lactam general capsules, beta‐lactam capsules, oral liquid, dry syrup and external preparations such as nasal spray, relief spray and creams. In addition, it is involved in the research of pharmaceutical molecules used in developing new pharmaceutical formulations; and manufacture of nutraceuticals and food products. The company also
1. Pharmaceuticals-This segment engages in the manufacturing of a range of pharmaceutical products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Sotac Pharmaceuticals Limited | ₹144 Cr | 24.8 | 10.29% | — | -0.4% |
Listed by market capitalisation. Ratios are shown for context only.
Sotac Pharmaceuticals Limited is trading at ₹129.35, with a market capitalisation of ₹144 Cr.
Sotac Pharmaceuticals Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Sotac Pharmaceuticals Limited has a P/E of 24.8 and a return on equity of 10.29%.
Sotac Pharmaceuticals Limited is listed on the NSE under the symbol SOTAC.
Sotac Pharmaceuticals Limited's share price is down 0.4% over one year and up 40.7% over three months. Its 52-week range is ₹86.00 to ₹139.65.
Promoters held 72.85% of Sotac Pharmaceuticals Limited's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.